Sources Comparative review of semaglutide and tirzepatide mechanisms (Pharmacological Research, ScienceDirect) A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity (Diabetes, American Diabetes Association) GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models (PMC) Anorectic and aversive effects of GLP-1 receptor agonism mediated by brainstem CCK neurons, modulated by GIP (PMC) Head-to-Head Trial Compares Weight Loss Drugs (Weill Cornell Medicine Newsroom, reporting NEJM SURMOUNT-5) Head-to-head comparison of tirzepatide and semaglutide for weight loss: systematic review and meta-analysis (PubMed) Are You a GLP-1 Nonresponder
CJC 1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH)
That said, clinicians should be aware of and inquire about sexual side effects
The gentle approach is to use fat like an accent, not the whole meal
You can transfer from another provider and continue on the same or an equivalent dosage
If you still find yourself experiencing unmanageable side effects, remain on the lower dose for the duration of your treatment.